公开(公告)号：KR1020110030852A

公开(公告)日：2011-03-24

申请号：KR1020090088480

申请日：2009-09-18

Applicant: 한림제약(주)

Inventor： 김진선 ,  이근혁 ,  최병선 ,  김재신 ,  박진하 ,  오미진 ,  김은미

IPC: A61K31/675 ,  A61P19/10 ,  A61K31/59 ,  A61K9/20

CPC classification number: A61K9/2077 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/2027 ,  A61K31/59 ,  A61K31/675 ,  A61K2300/00

Abstract: PURPOSE: A pharmaceutical composition containing bisphosphonate derivative and cholecalciferol for preventing or treating osteoporosis is provided to suppress bone absorption. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains risedronic acid or salt thereof, ibandronic acid or salt thereof and 24,000-50,000 IU of cholecalciferol. The composition is administered in tablet form. A pharmaceutical composition for osteoporosis contains: 24,000-50,000 IU of cholecalciferol dissolved in ethanol or ethanol solution; a first stabilizing agent of tocopherol acetate, butylhydroxy toluene, or butylhydroxyanisole; cholecalciferol-containing granules; 5-20 weight% of mannitol as a second stabilizing agent; and risedronic acid or salt thereof, ibandronic acid or salt thereof.

Abstract translation: 目的：提供含有双膦酸衍生物和胆钙化醇用于预防或治疗骨质疏松症的药物组合物，以抑制骨吸收。 构成：用于预防或治疗骨质疏松症的药物组合物含有利塞膦酸或其盐，伊班膦酸或其盐和24,000-50,000IU的胆钙化甾醇。 组合物以片剂形式施用。 用于骨质疏松症的药物组合物包含：溶解在乙醇或乙醇溶液中的24,000-50,000IU的胆钙化甾醇; 乙酸生育酚，丁基羟基甲苯或丁基羟基苯甲醚的第一稳定剂; 含胆钙化醇的颗粒; 5-20重量％的甘露醇作为第二稳定剂; 和利塞膦酸或其盐，伊班膦酸或其盐。